Featured Research

from universities, journals, and other organizations

New clues found to preventing lung transplant rejection

Date:
February 25, 2014
Source:
Washington University in St. Louis
Summary:
Broadly suppressing the immune system after lung transplantation may inadvertently encourage organ rejection, according to a new study in mice. Organ transplant patients routinely receive drugs that stop their immune systems from attacking newly implanted hearts, livers, kidneys or lungs, which the body sees as foreign. In a surprising discovery, researchers found that newly transplanted lungs in mice were more likely to be rejected if key immune cells were missing, a situation that simulates what happens when patients take immunosuppressive drugs.

Broadly suppressing the immune system after lung transplantation may inadvertently encourage organ rejection, according to a new study in mice. Pictured from left are study co-authors Daniel Kreisel, MD, PhD, Andrew Gelman, PhD, and Alexander Krupnick, MD.
Credit: Robert Boston

Organ transplant patients routinely receive drugs that stop their immune systems from attacking newly implanted hearts, livers, kidneys or lungs, which the body sees as foreign.

But new research at Washington University School of Medicine in St. Louis suggests that broadly dampening the immune response, long considered crucial to transplant success, may encourage lung transplant rejection.

In a surprising discovery, the researchers found that newly transplanted lungs in mice were more likely to be rejected if key immune cells were missing, a situation that simulates what happens when patients take immunosuppressive drugs.

These long-lived memory T cells are primed to "remember" pathogens that infiltrate the body and quickly trigger an immune response during subsequent encounters. In heart, liver and kidney transplants, knocking down memory T cells with immunosuppressive drugs helps to ensure that the immune system recognizes a new organ as the body's own.

But not so in lung transplants, according to the new research published online Feb. 24 in The Journal of Clinical Investigation.

"In mice, memory T cells are critical for a lung transplant to have a good outcome," said co-corresponding author Daniel Kreisel, MD, PhD, a Washington University lung transplant surgeon at Barnes-Jewish Hospital. "A lot of transplant recipients receive drugs that indiscriminately deplete many different T cells. But in lung transplants, this strategy may contribute to organ rejection."

In light of the new findings, the researchers think current immune-suppression strategies should be re-evaluated in lung transplantation.

"Most immunosuppressive drugs were adopted for use in lung transplants based on their results in other solid organ transplants, without an appreciation that the lung is different," Kreisel said.

The research also may help explain, in part, why the success of lung transplants in people lags far behind other solid organ transplants.

Five years after lung transplantation, fewer than half of the transplanted lungs are still functioning, according to the U.S. Organ Procurement and Transplantation Network. This compares with five-year organ survival rates of about 70 percent for heart, kidney and liver transplants.

The poorer outcomes after lung transplantation are related largely to higher rejection rates, the researchers said. About 1,800 lung transplants are performed each year in the United States.

"The high failure rate of lung transplants is a major problem," said co-corresponding author Alexander Krupnick, MD, a Washington University lung transplant surgeon at Barnes-Jewish Hospital. "Lungs are unique. Unlike other organs, they are continually exposed to bacteria, viruses and everything else in the environment, and we think this increases the risk of chronic rejection and the eventual failure of the organ."

Memory T cells regularly patrol the lungs, where they distinguish harmless challenges like cat dander or tree pollen from more serious insults like respiratory viruses or pathogenic bacteria. Without these cells, the immune system recognizes a newly transplanted lung as harmful and mounts an attack that eventually can lead to rejection of the organ.

As part of the study, the researchers performed lung transplants in mice. When memory T cells were absent in these mice, the newly transplanted lungs underwent rejection. The researchers found evidence of severe inflammation in the lungs, an indicator that the immune system had instigated an aggressive attack against the foreign organ.

However, when the scientists infused memory T cells into the lung recipients, they could reduce inflammation and prevent rejection. Further, they defined the molecular pathway by which memory T cells naturally dampen the body's response to lung transplants. Rather than attacking the lungs, memory T cells unleash a cascade of signaling molecules that encourage the immune system to see the transplanted lung as the body's own.

Based on their findings, the researchers want to find ways to selectively target immunosuppression in lung transplants, to encourage memory T cells to thrive while eliminating other T cells that harm transplanted lungs.

"We really need to develop immune suppression strategies just for lung transplants that boost the ability of memory T cells to do their job," Krupnick said. "This may give newly transplanted lungs a much better chance of surviving long after the transplant is over."


Story Source:

The above story is based on materials provided by Washington University in St. Louis. The original article was written by Caroline Arbanas. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexander Sasha Krupnick, Xue Lin, Wenjun Li, Ryuiji Higashikubo, Bernd H. Zinselmeyer, Hollyce Hartzler, Kelsey Toth, Jon H. Ritter, Mikhail Y. Berezin, Steven T. Wang, Mark J. Miller, Andrew E. Gelman, Daniel Kreisel. Central memory CD8 T lymphocytes mediate lung allograft acceptance. Journal of Clinical Investigation, 2014; DOI: 10.1172/JCI71359

Cite This Page:

Washington University in St. Louis. "New clues found to preventing lung transplant rejection." ScienceDaily. ScienceDaily, 25 February 2014. <www.sciencedaily.com/releases/2014/02/140225162556.htm>.
Washington University in St. Louis. (2014, February 25). New clues found to preventing lung transplant rejection. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140225162556.htm
Washington University in St. Louis. "New clues found to preventing lung transplant rejection." ScienceDaily. www.sciencedaily.com/releases/2014/02/140225162556.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins